Transcatheter Cardiovascular Therapeutics (TCT)

NewYork-Presbyterian is home to one of the largest structural heart programs in the nation and has helped pioneer transcatheter valve replacement techniques.

Graph depicting that surgical site infections decreased from 2012 to 2017Surgical Site Infection 2012 - 2017

Valve Disease Outcomes

NewYork-Presbyterian’s specialists in valvular heart disease are at the forefront of developing minimally invasive and catheter-based approaches to valve repair and replacement, influencing the field through clinical research that spans the medical, interventional and surgical arenas.

Learn more about our in-hospital mortality and surgical site infection rates consistently below expected values

Graph depicting that the volume grew each year from 2013 to 2017

Transcatheter Valve Procedures Volume 2013-2017

Aortic Valve Disease

At NewYork-Presbyterian, transcather therapy has become a mainstay of the treatment algorithm for structural heart disease. Over 4,000 TAVR procedures have been performed here since its introduction, and some 500 cases are performed annually by our heart teams.

Learn More


Mitral Valve device

Mitral Valve Disease

The technology and techniques now being studied in the treatment of mitral valve disease are providing patients who would have been excluded from treatment – the elderly or critically ill – the opportunity for meaningful therapy.